this is what my ChatGTP tells your ChatGTP
What’s Overstated or Omitted
Linda Powers' Conflict of Interest:
The write-up tries to sanitize this. Powers’ dual role as CEO of NWBO and control person of Cognate (via Toucan) was a governance red flag.
Even if disclosed and eventually unwound in 2018, this created perception issues and real shareholder concern for years.
“Strategic disentanglement” sounds poetic but let’s not sugarcoat: it was insider entanglement first.
Manufacturing ? Commercialization Readiness:
Having infrastructure doesn’t mean you’re ready to scale under market pressure.
Sawston only recently got GMP certification, and Flaskworks still needs regulatory validation. That’s not “we're ready” — that’s maybe soon.
“Delays Were Infrastructure”:
The idea that delays were all part of a master plan is classic revisionism.
MHRA and EMA had no frameworks for ECA-based approval. Powers took a huge regulatory gamble by submitting without such guidance. That’s not infrastructure delay. That’s bold but risky.
“Critics Hate It Because It’s Right”:
This rhetorical device ignores legitimate concerns.
NWBO still has:
No revenue.
No clear commercialization partners.
No proven payer strategy.
A highly dilutive capital structure.
Not all skepticism is “short-aligned bad faith.”
🤔 What’s Missing
Any mention of cash burn or investor dilution, which have been severe.
Any discussion of why it took 3+ years post-submission to get close to approval, which can't be explained solely by infrastructure.
The real impact of Flaskworks not being used for the MAA—it’s a huge part of the strategy but not yet regulatory-grade.
🧾 Bottom Line
Yes, NWBO made an early, smart bet on manufacturing.
Yes, Cognate was real, valuable, and deeply integrated.
But the write-up romanticizes this foresight, ignoring very real missteps, risks, and governance concerns.
Market Data 
Markets 
AI
